Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01364558 · ClinicalTrials.gov registry record · Phase 1

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

A Phase 1 study of Epilepsy, sponsored by University of Minnesota.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT01364558 is a Phase 1 study of Epilepsy that has completed, run by University of Minnesota. The registered enrollment target is 24 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01364558, a Phase 1 study of Epilepsy, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration

Conditions Studied

Interventions

  • DRUG Diazepam

Study Locations (1)

Minnesota

  • Prism Clinical Research Unit - Saint Paul

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-02
Est. Completion 2011-04
Phase Phase 1

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT01364558

The ClinicalTrials.gov registry entry for NCT01364558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Diazepam is the first listed.

NCT01364558 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01364558 about?

NCT01364558 is a clinical study titled "A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers". The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration

What is the current status of trial NCT01364558?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-02. Estimated completion is 2011-04.

What conditions does trial NCT01364558 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT01364558?

The interventions under investigation include: Diazepam (DRUG).

Who is sponsoring clinical trial NCT01364558?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01364558 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.